%D8%AB%D8%A7%D9%84%D9%8A%D8%AF%D9%88%D9%85%D9%8A%D8%AFTalidomida%D8%AA%D8%A7%D9%84%DB%8C%D8%AF%D9%88%D9%85%DB%8C%D8%AFTalidomidaCategory:ThalidomideThalidomidThalidomidThalidomidThalidomid%CE%98%CE%B1%CE%BB%CE%B9%CE%B4%CE%BF%CE%BC%CE%AF%CE%B4%CE%B7ThalidomideTalidomidoTalidomidaTalidomida%D8%AA%D8%A7%D9%84%DB%8C%D8%AF%D9%88%D9%85%DB%8C%D8%AFTalidomidiThalidomideTail%C3%ADdim%C3%ADdTalidomida%D7%AA%D7%9C%D7%99%D7%93%D7%95%D7%9E%D7%99%D7%93%E0%A4%A5%E0%A5%88%E0%A4%B2%E0%A4%BF%E0%A4%AF%E0%A5%8B%E0%A4%A1%E0%A5%8B%E0%A4%AE%E0%A4%BE%E0%A4%87%E0%A4%A1Thalidomid%D4%B9%D5%A1%D5%AC%D5%AB%D5%A4%D5%B8%D5%B4%D5%AB%D5%A4TalidomidaTalidomideTalidomide%E3%82%B5%E3%83%AA%E3%83%89%E3%83%9E%E3%82%A4%E3%83%89%E1%83%97%E1%83%90%E1%83%9A%E1%83%98%E1%83%93%E1%83%9D%E1%83%9B%E1%83%98%E1%83%93%E1%83%98%ED%83%88%EB%A6%AC%EB%8F%84%EB%A7%88%EC%9D%B4%EB%93%9C%D0%A2%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4ThalidomideThalidomidTalidomidTalidomida%D0%A2%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4Talidomid%E0%B6%AD%E0%B7%90%E0%B6%BD%E0%B7%92%E0%B6%B8%E0%B7%9C%E0%B6%BA%E0%B7%92%E0%B6%A9%E0%B7%8AThalidomideTalidomidTalidomid
about
sameAs
P1855
neurodermatitisgraft-versus-host diseaseerythema nodosumCrohn's diseasepyoderma gangrenosummyelofibrosisWaldenström's macroglobulinemiacutaneous lupus erythematosusCrohn's colitisrheumatoid arthritiscollecting duct carcinomaaphthous stomatitisAbïlmacroglobulinemiamultiple myelomalepromatous leprosyLetterer–Siwe diseaseamyloidosisBehcet's diseasemyelodysplastic syndrome
P2176
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaA Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaLenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin LymphomaClinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaSVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyPomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaAutologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaEvaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaPhase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceUARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionEfficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in RemissionTrial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISEA Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationPhase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMThe Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyPomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionPomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansAn Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular EczemaComparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple MyelomaVorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaMaintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)Phase II Study With CC-10004 in Psoriatic ArthritisThalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaR-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaSafety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate CancerLenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaA Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaA Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaThalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic SclerosisThalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid MetaplasiaLenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaLenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaGEM05 for Patients With Multiple Myeloma More Than 65 Years OldThalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
P4844
Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte subpopulation numbers in female B6C3F1 miceThalidomide for managing cancer cachexiaThalidomide for managing cancer cachexiaThalidomide and thalidomide analogues for maintenance of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseThalidomide for maintenance of remission in Crohn's diseaseThalidomide for induction of remission in Crohn's diseaseIdentification of a primary target of thalidomide teratogenicityThalidomide is an inhibitor of angiogenesisSecond malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenanceWhat is the functional role of the thalidomide binding protein cereblon?Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbitsSeven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseThalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationThalidomide analogues as anticancer drugsCANADIAN THALIDOMIDE EXPERIENCEBeneficial response to anakinra and thalidomide in Schnitzler's syndromeMutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathyThalidomide in the treatment of cancer cachexia: a randomised placebo controlled trialAntitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice.Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.Toxic substances and congenital malformationsDevelopmental Risks: Epidemiologic Advances in Health AssessmentZika: Worse Than Thalidomide?A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo NodularisEffective treatment of gastrointestinal bleeding with thalidomide--Chances and limitationsA case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide and dexamethasone and a review of the medical literatureVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceReview of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplasticThalidomide deformities and their nerve supply.Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomideStructure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsThalidomide mimics uridine binding to an aromatic cage in cereblonThalidomide-induced teratogenesis: history and mechanismsCyclooxygenase inhibitors derived from thalidomideThalidomide and its analogues as cyclooxygenase inhibitorsMechanisms of action and potential therapeutic uses of thalidomideThe role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myelomaThalidomide therapy and deep venous thrombosis in multiple myelomaDoxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
P921
Q1150378-C8059577-A713-4329-B1F7-2F03BDCCDB41Q1194520-2BD0F984-921D-463D-9830-26B35D57564DQ1363738-36C28CC3-6D24-4B9C-B414-7BD715AB245EQ1472-16D90029-E1D6-4F0D-8CDC-1F2D2787163EQ1526459-D59DE753-D722-4226-909F-C88B8049095DQ1752571-D67A1423-B6E4-47F9-A573-DA3D5B7E0B7DQ1778287-486E7387-CE0A-4B63-AAC6-65B04D2CCCB7Q18553226-0742E212-A47C-4A95-B292-813B4028B083Q18553712-A7FB87D6-911A-4D6D-9311-6B8700A47301Q187255-A5EB1051-666C-47B9-9F15-20A96D914F06Q18975905-F79E1A35-2E4A-412A-8E41-09D3976B15D5Q189956-F158AA37-506E-4F5E-B26A-393CCF6F5023Q36956-DFA3C738-0D14-4A01-9780-DB9E6A2A9794Q4118092-ED99F569-AF50-476D-AB33-DDEB8214519DQ467635-27D462B2-730B-4120-B6FB-BA8D16CB1313Q467635-CBB36BE0-4583-48AB-B9FA-853DFAC3B834Q6527832-DE32FC8A-031F-4190-95D7-1547531FCD96Q6533637-BA035E72-AC7D-432C-8B11-E31B18D19F7EQ816798-C07BF896-7DEA-4EC0-BE1D-E78ADFFC0D02Q911427-6339E1E1-C83A-4BF6-800D-C8ECA6744BA0Q954625-08744939-5992-41E5-BF1B-3D52E85108AA
P2176
description
Hipnotiko eta lasaigarri moduan erabilitako medikamentua.
@eu
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Tailídimíd
@ga
Talidomid
@sh
Talidomid
@sk
Talidomid
@sl
Talidomid
@sr-el
Talidomid
@sv
Talidomida
@ast
Talidomida
@eu
Talidomida
@gl
Talidomida
@id
type
label
Tailídimíd
@ga
Talidomid
@sh
Talidomid
@sk
Talidomid
@sl
Talidomid
@sr-el
Talidomid
@sv
Talidomida
@ast
Talidomida
@eu
Talidomida
@gl
Talidomida
@id
altLabel
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide
@en
(+-)-Thalidomide
@en
(±)-N-(2,6-dioxo-3-piperidyl)phthalimide
@en
(±)-thalidomide
@en
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline
@en
2,6-dioxo-3-phthalimidopiperidine
@en
3-Phthalimidoglutarimide
@en
50-35-1
@fr
C13H10N2O4
@fr
C13H10N2O4
@it
prefLabel
Tailídimíd
@ga
Talidomid
@sh
Talidomid
@sk
Talidomid
@sl
Talidomid
@sr-el
Talidomid
@sv
Talidomida
@ast
Talidomida
@eu
Talidomida
@gl
Talidomida
@id